Sotera Health Company (NASDAQ:SHC) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Sotera Health Company (NASDAQ:SHC) is currently rated as a "Moderate Buy" by five brokerages, with a consensus price target of $16.00.
• The company reported earnings of $0.20 per share, surpassing analysts' expectations of $0.17, with a revenue of $294.34 million for the quarter.
• Recent analyst actions include upgrades from Goldman Sachs and Wall Street Zen, which have increased their rating on Sotera Health to "buy" and "strong-buy", respectively.

Shares of Sotera Health Company (NASDAQ:SHC - Get Free Report) have been given an average rating of "Moderate Buy" by the five brokerages that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $16.00.

SHC has been the topic of several recent analyst reports. Barclays restated an "overweight" rating on shares of Sotera Health in a research note on Friday, August 8th. Piper Sandler lowered their target price on Sotera Health from $15.00 to $13.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. The Goldman Sachs Group upgraded Sotera Health from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $14.00 to $17.00 in a research note on Monday, May 5th. Finally, Wall Street Zen upgraded Sotera Health from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 16th.

Sotera Health Price Performance

Shares of NASDAQ:SHC opened at $16.30 on Thursday. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 4.49. The stock's fifty day simple moving average is $12.16 and its two-hundred day simple moving average is $12.14. Sotera Health has a 1-year low of $9.53 and a 1-year high of $17.08. The stock has a market cap of $4.63 billion, a PE ratio of 203.78 and a beta of 1.81.

Sotera Health (NASDAQ:SHC - Get Free Report) last issued its quarterly earnings data on Friday, August 8th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.03. Sotera Health had a return on equity of 39.42% and a net margin of 2.14%.The business had revenue of $294.34 million for the quarter, compared to analysts' expectations of $275.81 million. During the same period last year, the business earned $0.19 EPS. The business's revenue was up 6.4% on a year-over-year basis. Sotera Health has set its FY 2025 guidance at 0.750-0.820 EPS. As a group, analysts forecast that Sotera Health will post 0.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Sotera Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC grew its holdings in Sotera Health by 4,881.9% during the 1st quarter. Farther Finance Advisors LLC now owns 6,327 shares of the company's stock valued at $70,000 after buying an additional 6,200 shares in the last quarter. Teacher Retirement System of Texas purchased a new position in Sotera Health during the 1st quarter valued at about $266,000. BNP Paribas Financial Markets purchased a new position in Sotera Health during the 4th quarter valued at about $208,000. Principal Financial Group Inc. grew its holdings in Sotera Health by 0.3% during the 1st quarter. Principal Financial Group Inc. now owns 352,388 shares of the company's stock valued at $4,109,000 after buying an additional 1,037 shares in the last quarter. Finally, Ananym Capital Management LP purchased a new position in Sotera Health during the 4th quarter valued at about $13,680,000. 91.03% of the stock is currently owned by institutional investors.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.